KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Other Gross PP&E Adjustments (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Other Gross PP&E Adjustments readings, the most recent being -$335.0 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 7.71% to -$335.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$335.0 million, a 7.71% increase, with the full-year FY2025 number at $3.6 billion, down 15.16% from a year prior.
  • Other Gross PP&E Adjustments hit -$335.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $3.6 billion in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $6.1 billion in Q4 2022 to a low of -$464.0 million in Q1 2022.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$363.0 million (2025), compared with a mean of $740.1 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 97.65% in 2022 and later tumbled 38.95% in 2023.
  • Teva Pharmaceutical Industries' Other Gross PP&E Adjustments stood at $6.1 billion in 2022, then tumbled by 38.95% to $3.7 billion in 2023, then rose by 15.51% to $4.3 billion in 2024, then decreased by 15.16% to $3.6 billion in 2025, then tumbled by 109.25% to -$335.0 million in 2026.
  • The last three reported values for Other Gross PP&E Adjustments were -$335.0 million (Q1 2026), $3.6 billion (Q4 2025), and -$342.0 million (Q3 2025) per Business Quant data.